Association of Epstein Barr virus deoxyribonucleic acid with lung carcinoma

Jafarian, Amir Hossein; Omidi-Ashrafi, Abbsali; Roshan, Nema Mohamadian; Karimi-Shahri, Mahdi; Ghazvini, Kiarash; Boroumand-Noughabi, Samaneh

doi:10.4103/0377-4929.125290

Cited by 9 publications

(10 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, the only EBV-high sample from the TCGA cohort was collected from an Asian female patient (Table 6). This is consistent with the notion that the Asian population is more susceptible to EBV-associated lung cancer [20,56]. Our results support previous findings that in the lung cancer setting EBV is not restricted to the lymphoepithelioma-like carcinoma (LELC) subtype [14,15,16,17,18,19,20].…”

Section: Discussionsupporting

confidence: 92%

“…The first EBV-positive LC case was reported by Begin and colleagues in 1987 [7] and histologically it seems that the EBV-positive LCs are more likely to be the primary pulmonary lymphoepithelioma-like carcinoma, a relatively rare form of non-small cell lung cancer (NSCLC) preferentially occurring in Asian patients [8,9,10,11,12,13]. Meanwhile, the presence of EBV in lung squamous-cell carcinomas (LUSC) and lung adenocarcinomas (LUAD) was also reported by several studies [14,15,16,17,18,19,20].…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Detection of Epstein-Barr Virus Infection in Non-Small Cell Lung Cancer

Kheir

Zhao

Strong

et al. 2019

Cancers

View full text Add to dashboard Cite

Previous investigations proposed a link between the Epstein-Barr virus (EBV) and lung cancer (LC), but the results are highly controversial largely due to the insufficient sample size and the inherent limitation of the traditional viral screening methods such as PCR. Unlike PCR, current next-generation sequencing (NGS) utilizes an unbiased method for the global assessment of all exogenous agents within a cancer sample with high sensitivity and specificity. In our current study, we aim to resolve this long-standing controversy by utilizing our unbiased NGS-based informatics approaches in conjunction with traditional molecular methods to investigate the role of EBV in a total of 1127 LC. In situ hybridization analysis of 110 LC and 10 normal lung samples detected EBV transcripts in 3 LC samples. Comprehensive virome analyses of RNA sequencing (RNA-seq) data sets from 1017 LC and 110 paired adjacent normal lung specimens revealed EBV transcripts in three lung squamous cell carcinoma and one lung adenocarcinoma samples. In the sample with the highest EBV coverage, transcripts from the BamHI A region accounted for the majority of EBV reads. Expression of EBNA-1, LMP-1 and LMP-2 was observed. A number of viral circular RNA candidates were also detected. Thus, we for the first time revealed a type II latency-like viral transcriptome in the setting of LC in vivo. The high-level expression of viral BamHI A transcripts in LC suggests a functional role of these transcripts, likely as long non-coding RNA. Analyses of cellular gene expression and stained tissue sections indicated an increased immune cell infiltration in the sample expressing high levels of EBV transcripts compared to samples expressing low EBV transcripts. Increased level of immune checkpoint blockade factors was also detected in the sample with higher levels of EBV transcripts, indicating an induced immune tolerance. Lastly, inhibition of immune pathways and activation of oncogenic pathways were detected in the sample with high EBV transcripts compared to the EBV-low LC indicating the direct regulation of cancer pathways by EBV. Taken together, our data support the notion that EBV likely plays a pathological role in a subset of LC.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 97%

Detection of Epstein-Barr Virus Infection in Non-Small Cell Lung Cancer

Kheir

Zhao

Strong

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…In addition to the uncommon LELC subtype, emerging evidence has shown that EBV is also present in the tumor cells of conventional NSCLC subtypes including lung squamous-cell carcinomas (LUSC) and lung adenocarcinomas (LUAD) [ 41 , 42 , 43 , 44 , 45 , 46 , 47 ]. In addition to NSCLC, Chu and colleagues also detected EBV gene products such as EBNA1 and LMP1 in SCLC patients in the United States.…”

Section: Presence Of Ebv In Lung Cancersmentioning

confidence: 99%

“…The latest literature search was performed in March 2021. Having carefully evaluated the extracted studies, we selected 42 relevant studies and the EBV status in LCs was summarized in Table 2 [ 12 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 ].…”

Section: Presence Of Ebv In Lung Cancersmentioning

confidence: 99%

Pathogenic Role of Epstein–Barr Virus in Lung Cancers

Becnel

Abdelghani

Nanbo

et al. 2021

Viruses

View full text Add to dashboard Cite

Human oncogenic viruses account for at least 12% of total cancer cases worldwide. Epstein–Barr virus (EBV) is the first identified human oncogenic virus and it alone causes ~200,000 cancer cases and ~1.8% of total cancer-related death annually. Over the past 40 years, increasing lines of evidence have supported a causal link between EBV infection and a subgroup of lung cancers (LCs). In this article, we review the current understanding of the EBV-LC association and the etiological role of EBV in lung carcinogenesis. We also discuss the clinical impact of the knowledge gained from previous research, challenges, and future directions in this field. Given the high clinical relevance of EBV-LC association, there is an urgent need for further investigation on this topic.

show abstract

“…10 Recently, a variety of contributing factors, including viral infection, have been suggested in tumorigenesis. 11 Epstein-Barr virus (EBV), a herpesvirus classified as a group 1 carcinogen by the International Agency for Research in Cancer, 12 might be one of the potential cause to induce lung cancer. 13,14 As reported, lung cancer patients had higher EBV seropositivity than healthy controls.…”

mentioning

confidence: 99%

Retracted: Effects of ebv‐miR‐BART7 on tumorigenicity, metastasis, and TRAIL sensitivity of non‐small cell lung cancer

Wang

Liu²,

Zhou

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Objective: To investigate how the Epstein-Barr virus (EBV) encoded microRNA BART7 (miR-BART7) affects tumorigenicity, metastasis, and TRAIL sensitivity of non-small cell lung cancer (NSCLC). Methods: Real time-polymerase chain reaction was performed to detect miR-BART7 expression in NSCLC cell lines. A549 and Calu-1 cells transfected with miR-BART7 inhibitors/mimics were used to do the in-vitro experiments, including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Annexin V-fluorescein isothiocyanate/PI, wound-healing, transwell, clonogenic assays, Western blot analysis, and anchorage-independent growth assay.Additionally, mice were used to inject A549 cells infected with miR-BART7 inhibitors to observe the tumorigenicity and metastasis of NSCLC.Results: TRAIL-resistant NSCLC cell lines (H460R, A549, Calu-1, and H1299) exhibited higher miR-BART7 rather than sensitive H460 and H292 cells. After transfected with miR-BART7 inhibitors, we observed an inhibition in proliferation, migration, invasion, and colony formation, but an enhancement in apoptosis as well as expressions of caspase-3 and caspase-8 in A549 and Calu-1 cells.Besides, TRAIL elevated the migration, invasion, and anchorage-independent growth of A549 cells, which was reversed by silencing DR4 and DR5 (siDRs).However, miR-BART7 inhibitors could reduce migration, invasion, and transformation potential of TRAIL treated A549 cells. Moreover, the expression of transforming growth factor-beta 1 (TGFβ1) could be decreased by miR-BART7 inhibitors with or without TRAIL treatment. Moreover, the tumor growth, epithelial-to-mesenchymal transition, and metastasis was suppressed and tumorfree survival was extended after injection of A549-miR-BART7 inhibitors. Conclusion: Inhibition of miR-BART7 exerted inhibitory effects on cell proliferation, migration, invasion, and colony formation, consequently facilitating cell apoptosis and raising TRAIL sensitivity, providing a new therapeutic target in NSCLC. K E Y W O R D S apoptosis, ebv-miR-BART7, invasion, metastasis, non-small cell lung cancer (NSCLC), proliferation, TNF-related apoptosis-inducing ligand

show abstract

Association of Epstein Barr virus deoxyribonucleic acid with lung carcinoma

Cited by 9 publications

References 1 publication

Detection of Epstein-Barr Virus Infection in Non-Small Cell Lung Cancer

Detection of Epstein-Barr Virus Infection in Non-Small Cell Lung Cancer

Pathogenic Role of Epstein–Barr Virus in Lung Cancers

Retracted: Effects of ebv‐miR‐BART7 on tumorigenicity, metastasis, and TRAIL sensitivity of non‐small cell lung cancer

Contact Info

Product

Resources

About